

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Complete if Known

Application Number	09/814,123
Filing Date	March 22, 2001
First Named Inventor	Derk J. Hogenkamp
Examiner Name	Shameem, G.
Group Art Unit	1626
Attorney Docket No.	1861.1270001/JMC/THN

TOTAL AMOUNT OF PAYMENT (\$)**420.00**

METHOD OF PAYMENT (check one)

1. ☐ The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:

Deposit Account Number **19-0036**
Deposit Account Name **Sterne, Kessler, Goldstein & Fox P.L.L.C.**

- ☐ Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17

- ☐ Applicant claims small entity status See 37 CFR 1.27

2. ☒ Payment Enclosed:

- ☒ Check ☐ Credit card ☐ Money Order ☒ Other*

*Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 19-0036.

FEE CALCULATION

1. BASIC FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee	
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1) (\$) **0.00**

2. EXTRA CLAIM FEES

Total Claims	Extra	Fee from below	Fee Paid
29 - 25** = 4	X	18	72.00
Indep. Claims 7 - 5** = 2	X	84	168.00
Multiple Dependent			

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim
108	84	209	42	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) **240.00**

** or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	130	123	130	Petitions related to provisional applications	
126	180	126	180	Submission of Information Disclosure Stmt	180.00
581	40	481	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify):


Other fee (specify):

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) **180.00**

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	John M. Covert	Registration No. (Attorney/Agent)	38,759	Telephone	202-371-2600
Signature		Date	Dec. 13, 2001		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SKGF Rev. 10/01/01 mnac

REPLY, 111&IDS.FEE.WPD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hogenkamp *et al.*

Appl. No. 09/814,123

Filed: March 22, 2001

For: **Aryl Substituted Pyrazoles,
Triazoles and Tetrazoles, and
the Use Thereof**

Confirmation No. 2060

Art Unit: 1626

Examiner: Shameem, G.

Atty. Docket: 1861.1270001/JMC/THN

Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following, in regards to non-English language documents AL1 and AL2 cited on Form PTO 1449:

Document **AL1**, German Patent No. DE 19 36 760 is in the German language. An English language abstract of document AL1 is attached as document **AT15**.

Document **AM1**, German Patent No. DE 29 10 330 A1 is in the German language. An English language abstract of document AM1 is attached as document **AR16**.

Document **AL3**, Japanese Patent No. JP 11 199566 A is in the Japanese language. An English language abstract of document AL3 is attached as document **AS16**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our Check No. 33531 in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



John M. Covert
Attorney for Applicants
Registration No. 38,759

Date: Dec 13, 2001

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp et al.FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	3,049,438	08/14/1962	Buell and Long	117	33.5	11/03/1958
	AB1	3,058,989	10/16/1962	Buell and Long	260	296	11/26/1957
	AC1	4,072,498	02/07/1978	Moon et al.	71	92	05/14/1976
	AD1	4,394,514	07/19/1983	Kruse, L.I.	548	508	06/29/1981
	AE1	4,454,337	06/12/1984	Kruse, L.I.	560	22	03/02/1983
	AF1	4,639,266	01/27/1987	Heubach et al.	71	92	09/09/1985
	AG1	4,962,011	10/09/1990	Aldag et al.	430	281	05/17/1988
	AH1	5,134,142	07/28/1992	Matsuo et al.	514	255	09/14/1990
	AI1	5,670,533	09/23/1997	Matsuo et al.	514	106	12/28/1995
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	DE 19 36 760	01/22/1970	Germany			Abstract Yes No
	AM1	DE 29 10 330 A1	10/02/1980	Germany			Abstract Yes No
	AN1	GB 2 105 327 A	03/23/1983	Great Britain			Yes No
	AO1	EP 0 273 528 A1	07/06/1988	Europe			Yes No
	AP1	EP 0 323 841 A2	07/12/1989	Europe			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Arient, J. and Dvořák, J., "Triphenylmethane dyes. II. Introduction of the triazole group into the triphenylmethane skeleton," <i>Chem. Abstracts</i> 52:Abstract No. 12401i, The American Chemical Society (1958).
	AS	1	Baud, J., et al., "CGP 31358 binds to a site on the NMDA receptor that is coupled to both the transmitter recognition site and the channel domain," <i>Neurosci. Lett.</i> 107:184-188, Elsevier Scientific Publishers Ireland Ltd. (1989).
	AT	1	Bensimon, G., et al., "A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis," <i>New Eng. J. Med.</i> 330:585-591, Massachusetts Medical Society (1994).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 1861.1270001/JMC/THN

APPLICATION NO.
 09/814,123

APPLICANT
 Hogenkamp *et al.*

FILING DATE
 March 22, 2001

GROUP
 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	EP 0 323 841 A3	09/12/1990	Europe			Yes No
	AM2	EP 0 488 959 A2	06/03/1992	Europe			Yes No
	AN2	EP 0 323 841 B1	08/04/1993	Europe			Yes No
	A02	WO 96/11911	04/25/1996	WIPO			Yes No
	AP2	WO 97/07102	02/27/1997	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>2</u>	Brown, J.B. and Stammers, D.W., "Yellow color images by silver and dye bleaching," <i>Chem. Abstracts</i> 57:Abstract No. 12673d, The American Chemical Society (1962).
	AS	<u>2</u>	Brown, C.M., <i>et al.</i> , "Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia," <i>Br. J. Pharmacol.</i> 115:1425-1432, Stockton Press (August 1995).
	AT	<u>2</u>	Buchan, A.M., <i>et al.</i> , "AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists," <i>Suppl. 1 Stroke</i> 24:148-152, Lippincott Williams and Wilkins (1993).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 1861.1270001/JMC/THN

APPLICATION NO.
 09/814,123

APPLICANT
 Hogenkamp *et al.*

FILING DATE
 March 22, 2001

GROUP
 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL3	JP 11 199566 A	07/27/1999	Japan			Abstract Yes No
	AM3	WO 99/62885	12/09/1999	WIPO			Yes No
	AN3	WO 00/57877	10/05/2000	WIPO			Yes No
	A03	EP 1 081 146 A1	03/07/2001	Europe			Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	Catterall, W.A., "Structure and Function of Voltage-Sensitive Ion Channels," <i>Science</i> 242:50-61, American Association for the Advancement of Science (1988).
	AS	<u>3</u>	Catterall, W.A., "Neurotoxins That Act on Voltage-Sensitive Sodium Channels in Excitable Membranes," <i>Ann. Rev. Pharmacol. Toxicol</i> 20:15-43, Annual Reviews Inc. (1980).
	AT	<u>3</u>	Catterall, W.A., "Common modes of drug action on Na ⁺ channels: local anesthetics, antiarrhythmics and anticonvulsants," <i>Trends Pharmacol. Sci.</i> 8:57-65, Elsevier Science Publishers B.V. (1987).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp *et al.*FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>4</u>	Cocco, M.T., <i>et al.</i> , "Phytotoxic Activity in Pyrazole Derivatives II," <i>Il Farmaco Ed. Sc.</i> 40:272-284, Societa Italiana Di Scienze Farmaceutiche (1985).
	AS	<u>4</u>	Creveling, C.R., <i>et al.</i> , "Batrachotoxin-Induced Depolarization and [³ H] Batrachotoxinin-A 20 α -Benzoate Binding in a Vesicular Preparation from Guinea Pig Cerebral Cortex," <i>Mol. Pharmacol.</i> 23:350-358, The American Society for Pharmacology and Experimental Therapeutics (1983).
	AT	<u>4</u>	Dal Monte, D. and Veggetti, P., "Derivatives of pyrazolone and pyrazolyl carbamates," <i>Chem. Abstracts</i> 53:Abstract No. 8122f, The American Chemical Society (1959).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp *et al.*FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Denicoff, K.D., <i>et al.</i> , "Efficacy of Carbamazepine Compared With Other Agents: A Clinical Practice Survey," <i>J. Clin. Psychiatry</i> 55:70-76, Physicians' Postgraduate Press, Inc. (1994).
	AS	<u>5</u>	Dimmock, J.R., <i>et al.</i> , "Evaluation of the thiosemicarbazones of some aryl alkyl ketones and related compounds for anticonvulsant activities," <i>Eur. J. Med. Chem.</i> 26:529-534, Elsevier Science (1991).
	AT	<u>5</u>	Donaldson, I., "Tegretol: A double blind trial in tinnitus," <i>J. Laryngol. Otol.</i> 95:947-951, Royal Society of Medicine Press (1981).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp *et al.*FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>6</u>	Filer, C.N., "Chapter 6, The Preparation and Characterization of Tritiated Neurochemicals," <i>In: Isotopes in the Physical and Biomedical Sciences, Volume 1, Labelled Compounds (Part A)</i> , Buncel, E. and Jones, J.R. eds., pp.156-192, Elsevier Science Publishers B.V. (1987).
	AS	<u>6</u>	J.R. Geigy A.-G., "Diazo dyes," <i>Chem. Abstracts 60:Abstract No. 12144b</i> , The American Chemical Society (1964).
	AT	<u>6</u>	Graham, S.H., <i>et al.</i> , "Neuroprotective Effects of a Use-Dependent Blocker of Voltage-Dependent Sodium Channels, BW619C89, in Rat Middle Cerebral Artery Occlusion," <i>J. Pharmacol. Exp. Ther.</i> 269:854-859, The American Society for Pharmacology and Experimental Therapeutics (1994).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp *et al.*FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>7</u>	Graham, S.H., <i>et al.</i> , "A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia," <i>J. Pharmacol. Exp. Ther.</i> 276:1-4, The American Society for Pharmacology and Experimental Therapeutics (1996).
	AS	<u>7</u>	Hamill, O.P., <i>et al.</i> , "Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches," <i>Pflügers Arch.</i> 391:85-100, Springer-Verlag (1981).
	AT	<u>7</u>	Hunskaar, S. <i>et al.</i> , "Formalin test in mice, a useful technique for evaluating mild analgesics," <i>J. Neurosci. Methods</i> 14:69-76, Elsevier Science Publishers B.V.(1985).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 1861.1270001/JMC/THN

APPLICATION NO.
 09/814,123

APPLICANT
 Hogenkamp *et al.*

FILING DATE
 March 22, 2001

GROUP
 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>8</u>	Iwasaki, Y., <i>et al.</i> , "CNQX prevents spinal motor neuron death following sciatic nerve transection in newborn rats," <i>J. Neurosci.</i> 134:21-25, Elsevier Science B.V. (1995).
	AS	<u>8</u>	Kuo, C.-C. and Bean, B.P., "Slow Binding of Phenytoin to Inactivated Sodium Channels in Rat Hippocampal Neurons," <i>Mol. Pharmacol.</i> 46:716-725, The American Society for Pharmacology and Experimental Therapeutics (1994).
	AT	<u>8</u>	Lam, P.Y.S., <i>et al.</i> , "New Aryl/Heteroaryl C-N Bond Cross-coupling Reactions via Arylboronic Acid/Cupric Acetate Arylation," <i>Tetrahedron Lett.</i> 39:2941-2944, Elsevier Science Ltd. (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 1861.1270001/JMC/THN

APPLICATION NO.
 09/814,123

APPLICANT
 Hogenkamp *et al.*

FILING DATE
 March 22, 2001

GROUP
 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Majumdar, B., <i>et al.</i> , "An electrocochleographic study of the effects of lignocaine on patients with tinnitus," <i>Clin. Otolaryngol</i> 8:175-180, Blackwell Scientific Publications (1983).
	AS	2	Magagnoli, R., "1-(p-Benzoylphenyl)-3-alkyl(or benzamido)-5-pyrazolones as color couplers," <i>Chem. Abstracts</i> 65:Abstract No. 5576g, The American Chemical Society (1966).
	AT	2	Møller, A.R., "Similarities Between Chronic Pain and Tinnitus," <i>Am. J. Otol.</i> 18:577-585, Lippincott-Raven Publishers (1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 1861.1270001/JMC/THN

APPLICATION NO.
 09/814,123

APPLICANT
 Hogenkamp *et al.*

FILING DATE
 March 22, 2001

GROUP
 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>10</u>	Neeff, R., "Anilinoanthraquinone dyes," <i>Chem. Abstracts</i> 63:Abstract No. 11745g, The American Chemical Society (1965).
	AS	<u>10</u>	Ohizumi, Y., <i>et al.</i> , "Specific Inhibition of [³ H] Saxitoxin Binding to Skeletal Muscle Sodium Channels by Geographotoxin II, a Polypeptide Channel Blocker," <i>J. Biol. Chem.</i> 261:6149-6152, The American Society of Biological Chemists, Inc. (1986).
	AT	<u>10</u>	Pokorný, M. and Haase, J., "Substantive triphenodioxazine dyes containing a naphtho-[1,2- <i>d</i>] triazole nucleus," <i>Chem. Abstracts</i> 55:Abstract No. 7854i, The American Chemical Society (1961).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp *et al.*FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>11</u>	Polevoi, L.G., <i>et al.</i> , "Relation of aminopyrazole structures to their neurotropic activity," retrieved from STN, Database Accession No. 69:1557 CAPLUS, Chemical Abstracts Service (1968).
	AS	<u>11</u>	Ragsdale, D.S., <i>et al.</i> , "Frequency and Voltage-Dependent Inhibition of Type IIA Na ⁺ Channels, Expressed in a Mammalian Cell Line, by Local Anesthetic, Antiarrhythmic, and Anticonvulsant Drugs," <i>Mol. Pharmacol.</i> 40:756-765, Williams & Wilkins (1991).
	AT	<u>11</u>	Rasavi, D., "Reactive dyes," <i>Chem. Abstracts</i> 59:Abstract 6555g, The American Chemical Society (1963).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 1861.1270001/JMC/THN

APPLICATION NO.
 09/814,123

APPLICANT
 Hogenkamp *et al.*

FILING DATE
 March 22, 2001

GROUP
 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	Sheardown, M.J., <i>et al.</i> , "AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h," <i>Eur. J. Pharmacol.</i> 236:347-353, Elsevier Science Publishers B.V. (1993).
	AS	<u>12</u>	Simpson, J.J., and Davies, W.E., "Recent advances in the pharmacological treatment of tinnitus," <i>Trends Pharmacol. Sci.</i> 20:12-18, Elsevier Science London (1999).
	AT	<u>12</u>	Steck, E.A., <i>et al.</i> , "Some Guanazole Derivatives," <i>J. Am. Chem. Soc.</i> 80:3929-3931, The American Chemical Society (1958).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp *et al.*FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>13</u>	Steck, E.A., and Nachod, F.C., "Absorption Spectra of Heterocyclic Compounds. VII. Some 3(2H)-Pyridazones," <i>J. Am. Chem. Soc.</i> 79:4408-4411, The American Chemical Society (1957).
AS	<u>13</u>	Stefancich, G., <i>et al.</i> , "Analogues of Bifonazole with Two Imidazole Moieties and Related Azoles," <i>Arch. Pharm. (Weinheim)</i> 323:273-280, VCH Verlagsgesellschaft mbH (1990).
AT	<u>13</u>	Stys, P.K., <i>et al.</i> , "Ionic Mechanisms of Anoxic Injury in Mammalian CNS White Matter: Role of Na ⁺ Channels and Na ⁺ -Ca ²⁺ Exchanger," <i>J. Neurosci.</i> 12:430-439, Society for Neuroscience (1992).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 1861.1270001/JMC/THN

APPLICATION NO.
 09/814,123

APPLICANT
 Hogenkamp *et al.*

FILING DATE
 March 22, 2001

GROUP
 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>14</u>	Taylor, C.P., and Meldrum, B.S., "Na ⁺ channels as targets for neuroprotective drugs," <i>Trends Pharmacol. Sci.</i> 16:309-316, Elsevier Trends Journals (1995).
	AS	<u>14</u>	Tonndorf, J., "The analogy between tinnitus and pain: A suggestion for a physiological basis of chronic tinnitus," <i>Hear Res.</i> 28:271-275, Elsevier Science Publishers B.V. (1987).
	AT	<u>14</u>	Verdoorn, T.A., <i>et al.</i> , "Functional Properties of Recombinant Rat GABA _A Receptors Depend upon Subunit Composition," <i>Neuron</i> 4:919-928, Cell Press (1990).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp *et al.*FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>15</u>	Wrathall, J.R., <i>et al.</i> , "Amelioration of Functional Deficits from Spinal Cord Trauma with Systemically Administered NBQX, an Antagonist of Non-N-methyl-D-aspartate receptors," <i>Exp. Neurol.</i> 137:119-126, Academic Press, Inc. (1996).
	AS	<u>15</u>	Zweidler, R. and Keller, E., "Fluorescent ditriazole compounds," <i>Chem. Abstracts</i> 52:Abstract No. 8206c, The American Chemical Society (1958).
	AT	<u>15</u>	Dialog File 351, Accession No. 669110, Derwent WPI English Language abstract for DE 19 36 760 (Document AL1).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 1861.1270001/JMC/THN

APPLICATION NO.
 09/814,123

APPLICANT
 Hogenkamp *et al.*

FILING DATE
 March 22, 2001

GROUP
 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>16</u>	Dialog File 351, Accession No. 2553655, Derwent WPI English language abstract for DE 29 10 330 A1 (Document AM1).
AS	<u>16</u>	Dialog File 351, Accession No. 12667941, Derwent WPI English Language abstract for JP 11 199566 A (Document AL3).
AT	<u>16</u>	International Search Report for International Application No. PCT/US 01/08972, mailed September 24, 2001.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.